Drug Trial Radar · NCT06241560
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Mar 5, 2026
Primary completion
Aug 5, 2026
Study completion Aug 7, 2026
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Feb 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are 40 years and older. The purpose of this study is to find out whether a medicine called pirfenidone changes the amount of a medicine called BI 1015550 in the blood. Some people may take more than one medicine at a time. Therefore, it is important to understand how different medicines influence one another. Participants take one dose of BI 1015550 as a tablet. Participants then take one tablet of pirfenidone 3 times a day for one week. The dose is then increased to 2 tablets 3 times a day for the second week. In the third week the dose is increased further to 3 tablets 3 times a day. Participants then take another dose of BI 1015550 as a tablet. Participants are in the study for a little over 1 month. During this time, they visit the study site 15 times. Two of the visits include overnight stays at the study site. The study staff also contacts the participants by phone. During the visits, the doctors collect information about participants' health and take blood samples from the participants. They compare the amount of pirfenidone and BI 1015550 in the blood. Doctors also regularly check participants' health and take note of any unwanted effects.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
BI 1015550Drug
BI 1015550
PirfenidoneDrug
Pirfenidone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the concentration-time curve of nerandomilast in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)Time frame: Up to day 34
- Maximum measured concentration of nerandomilast in plasma (Cmax)Time frame: Up to day 34
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Renovatio Clinical-The Woodlands-69551
The Woodlands, Texas
LTD The First Medical Center
Tbilisi, Georgia
LTD "Aversi clinic"
Tbilisi, Georgia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.